Jiangsu Yahong Meditech Co Ltd
SHH: 688176.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ke Pan
- Employees
- 391
- Headquarters
- Shanghai, China
- IPO year
- 2022
- Market cap
- CN¥7.3B
- Website
- https://www.asieris.cn
Loading 688176…
Loading profile data…Frequently asked questions about 688176
What does Jiangsu Yahong Meditech Co Ltd (688176.SS) do?
Jiangsu Yahong Meditech Co., Ltd. engages in the research and development, production, and commercialization of drugs for genitourinary system tumors and other diseases in China and internationally. Its pipeline includes APL-1202, an anti-tumor drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; AP...
Where does 688176.SS trade?
Jiangsu Yahong Meditech Co Ltd (688176.SS) trades on the Shanghai Stock Exchange.
What sector is 688176.SS in?
Jiangsu Yahong Meditech Co Ltd (688176.SS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Jiangsu Yahong Meditech Co Ltd?
Ke Pan is the chief executive officer of Jiangsu Yahong Meditech Co Ltd (688176.SS).
Where is Jiangsu Yahong Meditech Co Ltd headquartered?
Jiangsu Yahong Meditech Co Ltd is headquartered in China.
Does 688176.SS pay a dividend?
Jiangsu Yahong Meditech Co Ltd (688176.SS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 688176.SS go public?
Jiangsu Yahong Meditech Co Ltd (688176.SS) completed its initial public offering in 2022.